ISDS 2025: Full Conference Recap

The 2025 Inflammatory Skin Disease Summit is complete! Check out our full recap below. To stay informed with the latest insights from conferences and beyond, subscribe to receive our eNewsletters and follow Dermatology Times on LinkedIn, Facebook, and X.

6th Inflammatory Skin Disease Summit: The Translational Revolution

Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.

Brian Kim, MD, MTR, FAAD, on the Power of Focus in Research

Kim explores the significance of inflammation in dermatology, revealing its connections to various diseases and the importance of focused research.

Triamcinolone Shows Transcriptomic Shifts in AD Within 24 Hours

Robert Bissonnette, MD, presented tape-strip transcriptomics detecting meaningful steroid responses after just 1 day of therapy.

Itch as a Window to Inflammation with Brian Kim, MD, MTR, FAAD

Chronic itching can reflect systemic disease, highlighting the importance of comprehensive assessment.

Targeting Metabolism to Control Effector and Regulatory T Cells

Therapeutic modulation of mitochondria offers a pathway to control multiple cytokine pathways simultaneously.

Rosenblum Reveals New Fibroblast–Immune Axis in Skin Inflammation

Michael Rosenblum’s team identified a previously underappreciated fibroblast subset that actively regulates inflammation, fibrosis, and microbial containment in the skin.

Immune Signatures Outperform Clinical Appearance in Treatment Guidance

Kilian Eyerich, MD, PhD, argues that classifying skin diseases by immune response patterns offers clearer therapeutic guidance than traditional morphology.

Brian Kim, MD, MTR, FAAD, Highlights Rapid Rise of Bioelectronic Medicine

Neuroimmune modulation, including vagus nerve stimulation, is highlighted as a promising strategy for patients unresponsive to biologics.

Ungar Explores Breakthroughs in Seborrheic Dermatitis and More

Benjamin Ungar, MD, shares groundbreaking insights on seborrheic dermatitis and emerging treatments in dermatology at ISDS 2025.

Cutaneous Lymphomas Offer Insights Into Chronic Skin Inflammation

Dupilumab clears AD clinically and histologically, but deep immune profiling shows disease-memory T cells persist in the skin.

Guselkumab Demonstrates Durable Joint-Protective Effects Through 48 Weeks in Active PsA

New long-term findings reveal guselkumab (TREMFYA) as the only IL-23 inhibitor effectively preventing joint damage in active psoriatic arthritis.

JAKs, STATs, and New Targets in Inflammatory Skin Disease

Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.